Rationale: The chemokine CXCL12 (CXC motif ligand 12) and its receptor CXCR 4 (CXC motif receptor 4) direct the recruitment of smooth muscle progenitor cells (SPCs) in neointima formation after vascular injury. Lysophosphatidic acid (LPA) induces CXCL12 and neointimal accumulation of smooth muscle cells (SMCs) in uninjured arteries. Thus, we hypothesize that LPA may regulate CXCL12-mediated vascular remodelling. Objectives: We evaluated the role of LPA receptors in initiating CXCL12-dependent vascular repair by SPCs. Methods and Results: Wire-induced carotid injury was performed in apolipoprotein E ؊/؊ mice on western-type diet. LPA receptor expression was studied by immunostaining and quantitative RT-PCR. LPA receptors LPA 1 and LPA 3 were detected in the media of uninjured arteries and in the injury-induced neointima. LPA 3 mRNA was upregulated and LPA 1 mRNA downregulated at one week after injury. The LPA 1/3 antagonist Ki16425 inhibited neointima formation by 71% and reduced both relative neointimal SMCs and the macrophage content. Additionally, neointimal hypoxia-inducible factor-1␣ and CXCL12 expression, the injury-induced peripheral stem cell antigen-1 (Sca-1) ؉ /Lin ؊ SPC mobilization, and the neointimal recruitment of Sca-1 ؉ SMCs were inhibited by Ki16425. In wild type mice, LPA20:4 increased CXCL12 and hypoxia-inducible factor-1␣ expression in carotid arteries as early as 1 day following short-term endoluminal incubation. LPA20:4-induced SPC mobilization and neointima formation were blocked by Ki16425, LPA 1 -and LPA 3 -specific small interfering (si)RNA, and the CXCR4 antagonist POL5551. Ki16425 reduced LPA20:4-mediated neointimal recruitment of SPC as demonstrated by 2-photon microscopy in bone marrow chimeric mice after repopulation with SM22-LacZ transgenic, hematopoietic cells. Moreover, POL5551 decreased the neointimal accumulation of CXCR4 ؉ SMCs. Conclusions: LPA 1 and LPA 3 promote neointima formation through activation of CXCL12-mediated mobilization and recruitment of SPCs. (Circ Res. 2010;107:96-105.)
T he response to mechanical vessel injury clinically encountered as restenosis after percutaneous interventions is characterized by the formation of neointimal tissue comprising primarily smooth muscle cells (SMCs) and leukocytes. 1, 2 Although drug-eluting stents have significantly reduced the need for repeated target vessel revascularization, long-term treatment with inhibitors of platelet aggregation after drug-eluting stent implantation to avoid late stent thrombosis is still a significant constraint. 3 Impaired endothelial recovery of drug-eluting stents is caused by the unspecific antimigratory and antiproliferative activities of drugs like Rapamycin or Paclitaxel and has been identified as a major risk factor for late stent thrombosis. 4 Therefore, development of alternative drugs which inhibit specifically neointimal SMC accumulation would be preferable. Apart from proliferation of neointimal SMCs, recruitment of circulating smooth muscle progenitor cells (SPCs) contributes decisively to the accumulation of SMCs in the neointima. [5] [6] [7] The chemokine CXCL12 (CXC motif ligand 12) and its receptor CXC motif receptor (CXCR)4 regulate the mobilization and recruitment of SPCs after vascular injury, 5, 6, 8 without affecting re-endothelialization. 9 Early apoptosis of medial SMCs and the nonhypoxic activation of the transcription factor hypoxia-inducible factor (HIF)-1␣ mediate the increased CXCL12 expression in the injured artery. 5, 10 In a diet-induced atherosclerosis model in mice, however, systemic inhibition of CXCR4 enhanced plaque formation by neutrophil mobilization representing a major caveat for long-term treatment. 11 Thus, exclusively local inhibition of injury-induced CXCL12 is required for the prevention of neointima formation to circumvent potential side effects of CXCR4 blockade.
Lysophosphatidic acid (LPA) is a structurally simple lipid phosphate ester with variability of the fatty acid chain length, saturation, and type of linkage to the glycerol backbone affecting its biological functions. 12, 13 Most of the LPA effects are mediated by at least seven specific G protein-coupled receptors comprising LPA receptor 1 (LPA 1 )/EDG2, LPA 2 /EDG4, and LPA 3 /EDG7 from the endothelial differentiation gene (Edg) family. All of them have specific functions in development and disease as revealed by LPA-deficient mice. 14 LPAs are generated after platelet activation in a two-step process from phospholipids involving phospholipase A2 and autotaxin. [15] [16] [17] Furthermore, LPA is an active component of mildly-oxidized LDL particles, accumulates in atherosclerotic plaques and induces the activation of endothelial cells and platelets. 18, 19 Short term incubation of uninjured carotid arteries with unsaturated LPAs results in neointimal hyperplasia containing exclusively SMCs. 20, 21 Among a variety of unsaturated LPA species, LPA20:4 (1-arachidonoyl-2-lyso-sn-glycero-3-phosphate) and the alkyl-ether analog 1-AGP18:1 (1-oleyl-2-lyso-sn-glycero-3phosphate) have been shown to stimulate neointimal growth in rats most efficiently. 20 Although LPA serves as a mitogenic growth factor for SMCs in vitro, 22 the exact mechanism of LPA-induced neointima formation remains unclear. Interestingly, in contrast to mice with combined deficiency of LPA 1 and LPA 2 , neointimal hyperplasia after carotid ligation was enhanced in LPA 1 Ϫ/Ϫ mice. This finding suggests a major role of Edg family LPA receptors in vascular repair. 23 In vitro, unsaturated LPA induces CXCL12 expression, which is inhibited by the LPA 1 and LPA 3 receptor antagonist Ki16425. 24 We therefore hypothesize that any blocking of the LPA receptors LPA 1 and LPA 3 reduces CXCL12 expression after vascular injury which implicates diminished neointima formation via SPC recruitment. Our studies demonstrate that treatment of apolipoprotein (apo)E Ϫ/Ϫ mice with Ki16425 after carotid wire-injury significantly reduced neointima formation and SMC accumulation. Moreover, HIF-1␣ and CXCL12 expression was upregulated in the vessel wall through LPA20:4 and inhibited by Ki16425 after vascular injury. LPA20:4-induced SPC mobilization and neointima formation is dependent on CXCR4 and both LPA 1 and LPA 3 .
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org and includes details regarding the following: histological analysis, ELISA, and quantitative (q)RT-PCR.
Mouse Models of Neointima Formation
Wire-induced injury of the common carotid artery in female apoE Ϫ/Ϫ mice (Jackson Laboratory) on high fat diet was performed as previously described. 5 ApoE Ϫ/Ϫ mice were treated with the LPA 1/3 receptor antagonist Ki16425 (5 mg/kg per day, Sigma, nϭ6) or 10% DMSO (nϭ5) by intraperitoneal injection for a period of 3 weeks. 25 In addition, endoluminal incubation of carotid arteries with different LPA species with or without Ki16425 for 30 minutes was performed in C57BL/6 mice (Charles River, Sulzfeld, Germany; Nϭ4 to 6 per group). Some mice were treated with the CXCR4 antagonist POL5551 (20 mg/kg per day, IP, Polyphor Ltd) or PBS (nϭ5 per group) for 4 weeks. In a separate experiment, carotid arteries were treated by perivascular application of nontargeting small interfering (si)RNA, CXCL12-, LPA 1 -, or LPA 3 -specific siRNA (4 nmol of LPA 1 , 3 nmol LPA 3 , 4 nmol CXCL12, or 4 nmol nontargeting siRNA, Accell SMART pool, Dharmacon, Nϭ3 to 6 per group) dissolved in 35% pluronic gel (Sigma Aldrich). After four days, arteries were incubated with LPA20:4 as described above. Perfusion fixation with 4% buffered paraformaldehyde was performed after 28 days. Animal experiments were reviewed and approved by local authorities in accordance with the German animal protection law. See the Online Data Supplement.
Bone Marrow Transplantation
Transplantation of bone marrow cells from SM22-LacZ mice, which express LacZ under the SM22 promoter 26 into C57BL/6 mice was performed as described. 6 See the Online Data Supplement.
Two-Photon Laser Scanning Microscopy
At 4 weeks after LPA 20:4 incubation with or without Ki16425 (Nϭ3 mice per group) the excised carotid arteries including the bifurcation area were mounted in a perfusion chamber and imaged with two photon laser scanning microscopy. 27, 28 See the Online Data Supplement.
Western Blot
Proteins were isolated from carotid arteries, separated by gel electrophoresis, and transferred to nitrocellulose membrane as described previously. 10 See the Online Data Supplement.
Flow Cytometry
Sca-1 ϩ /lincells were analyzed in anticoagulated blood by flow cytometry (FACSCalibur, BD Bioscience; CellQuestTM) in a mononuclear cell gate. 5, 10 See the Online Data Supplement.
Blood Chemistry
Serum samples were analyzed by dry chemistry using a Vitros 250 Analyzer (Ortho Clinical Diagnostics). 
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Statistical Analysis
Data represent meansϮSEM and were compared by either a t test, 1-or 2-way ANOVA followed by Newman-Keuls post test when appropriate (Prism, GraphPad). Differences with PϽ0.05 were considered statistically significant.
Results
Expression of LPA Receptors After Vascular Injury
As revealed by immunostaining, LPA 1 and LPA 3 are expressed in the media of uninjured carotid arteries (Online Figure I , A and B). At 1 and 2 weeks after vascular injury, staining for both receptors was predominantly observed in the neointima ( Figure  1A and B, Online Figure I, D through I). At 2 weeks, endothelial LPA 1 expression was detected by double immunostaining with von Willebrand factor (vWF) ( Figure 1A ), whereas LPA 3 was primarily evident in Mac-2 positive macrophages ( Figure 1B ). In uninjured apoE ϩ/ϩ mice on regular diet, LPA 1 mRNA expression is 1.8-times and 2.4-times greater than LPA 2 and LPA 3, respectively ( Figure 1C ). LPA 2 mRNA in carotid arteries was reduced by hyperlipidemia, whereas LPA 1 and LPA 3 expression were not significantly different from normolipidemic mice ( Figure 1C ). Following vascular injury, LPA 1 mRNA was downregulated at 1 and 2 weeks. In contrast, LPA 2 and LPA 3 expression was induced with a peak at 1 week after injury ( Figure 1C ). These results demonstrate differential regulation of LPA receptors after vascular injury with prominent vascular expression of LPA 1 and LPA 3 .
LPA 1 and LPA 3 Blockade Inhibits Neointima Formation and CXCL12 Activity
Treatment with Ki16425 reduced the neointimal hyperplasia by 71% compared to control buffer injection at 4 weeks, without modifying the medial and luminal areas ( (Online Figure IV) . Furthermore, neointimal HIF-1␣ ( Figure  3A through 3C) and CXCL12 ( Figure 3D through 3F) expression at 28 days after wire-injury was significantly reduced in Ki16425-treated mice as determined by immunostaining. Mobilization of Sca-1 ϩ /Lin Ϫ cells into the circulation after wire-injury and neointimal recruitment of Sca-1 ϩ / ␣-SMA ϩ cells was blocked by Ki16425 ( Figure 4 ). Noteworthy, Ki16425 did not affect serum cholesterol, triglycerides, alanine transaminase, and creatinine levels (data not shown). Although the changes of the SMC-and Mac-2specific immunopositive area may not directly represent differences in the actual cell numbers, it suggests that LPA 1 and LPA 3 are involved in vascular remodelling after injury by promoting the CXCL12-dependent recruitment of circulating SPCs and neointimal macrophage accumulation. Of note, LPA20:4 treatment of ex vivo perfused carotid arteries increased the adhesion of monocytic cells in a CXCR4dependent but also CXCR2-dependent manner (Online Figure V) , implying a direct role of LPA in atherogenic monocyte recruitment.
LPA 20:4 and 1-AGP Induce CXCL12 and HIF-1␣ Expression
To investigate the molecular mechanism of LPA-induced neointima formation in more detail, carotid arteries of C57BL/6 wild-type mice were incubated with saturated and unsaturated LPA species. CXCL12 expression was barely detectable by immunostaining in the vessel wall 28 days after PBS ( Figure  5A ) or LPA18:0 treatment ( Figure 5B ) (0.4Ϯ0.2% and 2.0Ϯ0.9%). In contrast, 1-AGP18:1 and LPA20:4 induced prominent CXCL12 expression in neointimal cells ( Figure 5C and 5D). The vessel wall area with CXCL12-specific staining was clearly increased after 1-AGP18:1 (6.5Ϯ1.0%, PϽ0.01) or LPA20:4 (10.4Ϯ0.6%, PϽ0.001) compared to PBS or LPA18:0. In addition, CXCL12 expression was higher after LPA20:4 compared to 1-AGP18:1 (PϽ0.01). Correspondingly, strong HIF-1␣ expression predominantly in neointimal cells was detectable in 1-AGP-18:1 and LPA20:4-( Figure 5G and 5H) , but not in PBS-and LPA18:0-treated arteries ( Figure 5E and  5F) . HIF-1␣-positive vessel wall area was increased by LPA20:4 (12.6Ϯ2.0%, PϽ0.001) or 1-AGP-18:1 (9.0%Ϯ0.7%, PϽ0.01) compared to PBS (0.4Ϯ0.1%) or LPA18:0 (1.2Ϯ0.1%). Moreover, the area with HIF-1␣-specific staining was more extended in LPA20:4-than in 1-AGP18:1-treated arteries (PϽ0.01). Following LPA20:4 treatment, cellular colocalization of nuclear HIF-1␣ and CXCL12 in neointimal cells was demonstrated by double immunostaining (Online Figure VI) . Time course experiments revealed upregulation of HIF-1␣ and CXCL12 as early as 1 day after LPA20:4 incubation. Persistently elevated HIF-1␣ and CXCL12 levels in the vessel wall were evident at 9 and 28 days as compared to untreated controls ( Figure 5I and 5J). These findings indicate that unsaturated LPAs induce prolonged CXCL12 and HIF-1␣ expression in the vessel wall.
SPC Mobilization by Unsaturated LPAs
CXCL12-mediated mobilization of Sca-1 ϩ /Lin Ϫ cells comprising SPCs is critical in wire-induced neointima formation. 5, 6 Therefore, circulating Sca-1 ϩ /Lin Ϫ cells were analyzed after endoluminal treatment of carotid arteries with different LPA species ( Figure 6A ). Whereas PBS, LPA18:0, and 1-AGP18:1 had no effect after 24 hours, LPA20:4 transiently increased the circulating Sca-1 ϩ /Lin Ϫ cells ( Figure 6A ). In contrast, systemic administration of LPA20:4 decreased the number of Sca-1 ϩ / Lin Ϫ cells after 24 hours (Online Figure VII) . After 9 days, however, when Sca-1 ϩ /Lin Ϫ cells returned to baseline after LPA20:4 incubation, mobilization of Sca-1 ϩ /Lin Ϫ cells was detected in 1-AGP18:1-treated mice ( Figure 6C ). On day 28, Sca-1 ϩ /Lin Ϫ cells were indistinguishable from controls in all analyzed groups (data not shown). LPA20:4-and 1-AGP18:1induced SPC mobilization was blocked by coincubation with Ki16425 at 24 hours and 9 days, respectively ( Figure 6B and 6C), suggesting that SPC mobilization by unsaturated LPA is mediated through LPA 1 or/and LPA 3 . In addition, the CXCR4 antagonist POL5551 prevented the LPA20:4-induced expansion of peripheral Sca-1 ϩ /Lin Ϫ cells, which express CXCR4 (Online Figure VIII) , demonstrating the involvement of the CXCL12/ CXCR4 axis ( Figure 6B ).
LPA-Induced Neointima Formation Depends on CXCR4 and Recruitment of Bone Marrow-Derived SPCs
Neointimal tissue was not evident after 28 days following PBSor LPA18:0 incubation ( Figure 7A ). In contrast, LPA20:4 or 1-AGP18:1 induced significant neointimal hyperplasia ( Figure  7A ) consisting mainly of SMCs (data not shown), which was reduced by coincubation with Ki16425 ( Figure 7A ). In addition, systemic treatment with POL5551 ( Figure 7C ), but not PBS ( Figure 7B ) completely inhibited neointima formation by LPA20:4. In LPA20:4-incubated carotid arteries, neointimal LacZ ϩ cells were detectable in mice transplanted with SM22-LacZ transgenic bone marrow cells by TPLSM ( Figure 7D and Online Video 1). Furthermore, the majority of medial SMCs did not reveal any ␤-galactosidase activity. After coincubation of LPA20:4 and Ki16425, however, LacZ ϩ cells were barely evident in the vessel wall ( Figure 7E and Online Video 2). Of note, the absence of LacZ-SM22 bone marrow cells was associated with only negligible background fluorescence ( Figure 7F and Online Video 3). Similar results were obtained by immunostaining for ␤-galactosidase (Online Figure IX) . This suggests that neointima formation by LPA20:4 is mediated through recruitment of bone marrow-derived SPCs via the LPA 1 or/and LPA 3 receptors. 50 m (A, B, E, and F) and  25 m (C, D, G, and H) . Elevated HIF-1␣ levels were evident by Western analysis as early as 1 day after LPA20:4 incubation (I). I, HIF-1␣ band intensity was normalized to the GAPDH signal (representative Western blot from 3 independent experiments is shown). J, Quantification of CXCL12 protein content in carotid arteries by ELISA after LPA20:4 treatment provided similar results. *PϽ0.05 vs control (Nϭ3 to 5 mice per group).
Inhibition of CXCR4 Impairs Accumulation of CXCR4 ؉ SMCs After LPA Treatment
In transplant arteriosclerosis, neointimal CXCR4 ϩ SMCs have been shown to derive predominantly from circulating progenitor cells. 29 Double immunostaining for CXCR4 and ␣-SMA after LPA20:4 treatment revealed prominent accumulation of CXCR4 ϩ SMCs in the neointima (Online Figure X) . After application of POL5551, only a minor part of the medial SMCs were CXCR4 ϩ (Online Figure X) , similar to what has been observed in untreated carotid arteries (Online Figure X) .
LPA20:4 Treatment Induces SPC Mobilization and Neointima Formation through LPA 1 and LPA 3
Knock-down of LPA 1 and LPA 3 at 4 days after perivascular application of LPA 1 -and LPA 3 -specific siRNA dissolved in pluronic gel was verified by qRT-PCR (data not shown). LPA 1 , LPA 3 , and CXCL12 siRNA treatment as compared to nontargeting siRNA inhibits the mobilization of Sca-1 ϩ /Lin Ϫ cells 24 hour after LPA20:4 incubation ( Figure 8A ). Following LPA20:4 incubation, the neointimal area in LPA 1 , LPA 3 , and CXCL12 siRNA-treated mice was reduced compared with nontargeting siRNA-treated mice ( Figure 8B ), implying that LPA 1 and LPA 3 are independently involved in LPA20:4-induced neointima formation via CXCL12.
Discussion
In this study, we demonstrated for the first time a critical role of the LPA receptors LPA 1 and LPA 3 in neointima formation after vascular injury in mice. In contrast to the vascular LPA receptor profile in rats, both LPA 1 and LPA 3 are predominantly expressed in medial SMCs in carotid arteries of hyperlipidemic mice. Treatment with the LPA 1 and LPA 3 receptor antagonist Ki16425 profoundly reduced neointimal hyperplasia owing to diminished neointimal accumulation of both SMCs and macrophages. Furthermore, HIF-1␣ and CXCL12 expression were reduced in the neointima of Ki16425-treated mice. This was associated with diminished mobilization and recruitment of SPCs. Because LPA20:4 induces neointima formation by CXCL12/CXCR4-mediated mobilization and recruitment of bone marrow-derived SPCs through LPA 1 and LPA 3 , we conclude that this is the crucial mechanism for the reduced neointimal SMC content in Ki16425-treated mice after vascular injury.
The neointimal accumulation of SMCs in wire-injured carotid arteries is regulated to a significant extent by the CXCL12/ CXCR4 axis, which induces the mobilization and recruitment of SPCs to the injury site. 5, 6, 8 Increased HIF-1␣ activation by nonhypoxic transcriptional upregulation mediates enhanced CXCL12 expression in the injured artery. 10 Unsaturated LPAs have been shown to upregulate CXCL12 expression in vitro in a LPA 1 and/or LPA 3 -dependent manner. 24 Moreover, LPAdependent HIF-1␣ activation has been reported in cancer cells leading to the upregulation of HIF-1␣-target genes. 30 We could confirm that LPA20:4 induces HIF-1␣ and CXCL12 in the vessel wall as early as 1 day after endoluminal incubation, which causes mobilization and recruitment of SPCs and thereby neointima formation. In contrast, 1-AGP18:1-induced SPC mobilization at a delayed time point which might be attributable to the diminished CXCL12 expression in the vessel wall. The administration of Ki16425 after carotid wire injury not only reduced the neointimal expression of CXCL12 and HIF-1␣, but also blunted the CXCL12-dependent mobilization of SPCs, suggesting an important role of LPAs and the LPA receptors LPA 1 and LPA 3 . Activated platelets are an important source of LPA20:4 precursors 31 and might substantially increase the concentration of unsaturated LPAs in the vessel wall early after endothelial denudation. Furthermore, injury-induced apoptosis of SMCs causes the release of microvesicles, which induce CXCL12 after vascular injury 6 and enhance LPA generation by providing LPA precursors. 32, 33 After LPA incubation of rat carotid arteries, where LPA 3 is not expressed, the LPA receptor antagonist DGPP (dioctylglycerol pyrophosphate), which inhibits predominantly LPA 3 but also LPA 1 , 34 partially reduced neointima formation. 20 In a blood flow cessation model, neointima formation was exaggerated in LPA 1 Ϫ/Ϫ mice, which was attributed to a compensatory increase of LPA 3 expression. 23 This is in line with our finding that LPA20:4-induced neointima formation is independently mediated by both LPA 1 and LPA 3 as demonstrated after siRNAmediated knock-down and adverts to potential limitations of the use of LPA 1 Ϫ/Ϫ mice in this context. Our results indicate that short term knock-down of either LPA 1 or LPA 3 by siRNA, which may avoid the compensatory upregulation observed in constitutive knock-out mice, is sufficient to inhibit the effect of LPA on vascular remodeling. However, when using a long-term treatment strategy combined inhibition of LPA 1 and LPA 3 may be required. Similarly to their overlapping function in vascular remodeling, LPA 1 and LPA 3 separately mediate LPA-induced CC motif ligand 2 (CCL2) and interleukin-8 expression. 35 In a recent study, neointima formation after 1-AGP incubation of carotid arteries in LPA 1 Ϫ/Ϫ mice was not diminished. 36 However, the potential role of increased LPA 3 expression has not been evaluated in this model. Of note, peroxisome proliferatoractivated receptor (PPAR)-␥ Ϫ/Ϫ mice were protected from 1-AGP-induced neointima formation. 36 Although we cannot exclude the activation of different signal pathways because of varying 1-AGP concentrations and incubation times used, HIF-1␣-induced activation of PPAR-␥ has been described in cardiac hypertrophy, 37 which may provide a direct link between the prima facie divergent mechanisms. Moreover, LPA20:4-induced PPAR-␥ activation was partially inhibited by the LPA 1/3 antagonist DGPP in vitro indicating the contribution of LPA receptors. 20 In addition to SMC accumulation, the Mac-2-immunopositive neointimal area was also diminished by Ki16425 suggesting that LPA receptors may play a role in macrophage recruitment. Of note, LPA 1 and LPA 3 are involved in LPA-induced monocyte adhesion to endothelial cells via nuclear factor Bdependent upregulation of CCL2 and interleukin-8. 35, 38, 39 Although the CXCL12/CXCR4 axis, in contrast to CCL2/CC motif receptor 2, has previously not been shown to affect neointimal macrophage content after vascular injury in apoE Ϫ/Ϫ mice, 5, 6, 9, 40 we found that LPA20:4 induced adhesion of monocytic cells in ex vivo-perfused carotid arteries in a CXCR4-dependent manner. However, inhibition of CXCR2, which is crucial in atherogenic monocyte recruitment, 41 similarly reduced LPA20:4-induced monocyte arrest, which indicates a concerted contribution of CXCR4 and CXCR2 possibly through miscellaneous ligands. Concordantly, we observed that LPA-induced monocyte adhesion is reduced by blocking endothelial LPA receptors. 42 In addition, atherogenic monocyte recruitment by LPA may require long term exposure, because macrophages were rarely found in the neointima after intravascular LPA incubation.
In summary, unsaturated LPAs and the LPA receptors LPA 1 and LPA 3 play a central role in the initiation of the CXCL12mediated vascular remodeling through circulating SPCs after vascular injury. Moreover, long-term treatment with an LPA 1 and LPA 3 antagonist reduces atherogenic monocyte recruitment. Therefore, joint inhibition of LPA 1 and LPA 3 is a promising approach to prevent neointima formation after stent implantation in arteries with obstructive atherosclerosis.
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